Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN 1/20 vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy,Oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Norethindrone: 7.6 hours (range 5-14); Ethinyl estradiol: 13.2 hours (range 8-20). Clinical context: Steady-state achieved within 5-10 days.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes first-pass metabolism in gut and liver. Norethindrone: primarily metabolized by reduction and conjugation; substrate of CYP3A4.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Approximately 60% renal (30% norethindrone, 30% ethinyl estradiol metabolites) and 40% fecal (biliary excretion of conjugates).
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Norethindrone: 61% (albumin, SHBG); Ethinyl estradiol: 97% (albumin).
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Norethindrone: 3.8 L/kg; Ethinyl estradiol: 2.8 L/kg. Indicates extensive tissue distribution.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral: Norethindrone 64% (first-pass metabolism); Ethinyl estradiol 38-48% (first-pass metabolism).
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (GFR <30 m L/min) due to potential fluid retention and metabolic acidosis.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Contraindicated in acute hepatic disease, hepatic adenomas, or severe cirrhosis (Child-Pugh class C). No specific dose adjustments provided for mild to moderate impairment; use caution.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults: one tablet orally once daily for 21 days followed by 7 placebo days.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Not indicated for use after menopause. No specific dose adjustments in elderly; increased risk of thrombosis and hypoglycemia warrants caution.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and with heavy smoking (≥15 cigarettes/day). Women who use combination hormonal contraceptives should not smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Thrombotic disorders: discontinue if thrombophlebitis, thromboembolic, or vascular events occur,Carcinoma risk: increased risk of breast cancer; cervical cancer association,Hepatic effects: acute liver disease, liver tumors,Elevated blood pressure,Gallbladder disease,Carbohydrate/lipid metabolic effects,Ocular lesions: retinal thrombosis; discontinue if unexplained vision loss,Hereditary angioedema exacerbation,Chloasma,Pregnancy: discontinue if pregnancy occurs
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Thrombophlebitis or thromboembolic disorders,History of deep vein thrombosis or pulmonary embolism,Cerebrovascular or coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Heavy smoking (≥15 cigarettes/day) in women >35 years
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
Grapefruit and grapefruit juice may increase estrogen levels; limit intake. No other significant food interactions. Avoid St. John's wort (herbal supplement) as it reduces contraceptive efficacy. Alcohol may increase risk of liver toxicity; moderate consumption is generally acceptable.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
LARIN 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from low-dose OCs in cohort studies, but an increased risk of cardiovascular malformations (e.g., VSD, TGA) and neural tube defects has been suggested in some studies; risk of oral cleft is not increased. Second/third trimesters: Use may increase risk of fetal hepatic adenoma, fetal feminization with androgenic progestins (norethindrone has minimal androgenicity), and potential for neonatal withdrawal bleeding or hormonal effects; no clear risk of pregnancy loss beyond baseline.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Small amounts of ethinyl estradiol and norethindrone pass into breast milk; combined OCs are generally not recommended during breastfeeding, especially in early lactation, as they may reduce milk quantity and quality. M/P ratio: Not established for LARIN 1/20; ethinyl estradiol M/P ratio is ~0.2-0.4, norethindrone M/P ratio ~0.1. Infants exposed via milk show no significant adverse effects, but theoretical risks include jaundice, breast enlargement, and long-term carcinogenicity. Use of progestin-only contraceptives is preferred.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
LARIN 1/20 is contraindicated in pregnancy; no dose adjustment recommended because drug should be discontinued immediately if pregnancy is detected. Pharmacokinetic changes in pregnancy (e.g., increased clearance, decreased SHBG, increased volume of distribution) would theoretically require higher doses if used, but use is not indicated. No standard dosing for use during gestation.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
LARIN 1/20 (norethindrone acetate 1 mg/ethinyl estradiol 20 mcg) has a low estrogen dose, which may reduce estrogen-related side effects but can increase breakthrough bleeding. It is a monophasic pill. Starting on the first day of menses provides immediate contraceptive protection. Caution in patients with migraine with aura or uncontrolled hypertension. Check for drug interactions with CYP3A4 inducers (e.g., rifampin, St. John's wort).
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take one pill daily at the same time; missing pills increases pregnancy risk.,If you miss a pill, follow the package instructions; use backup contraception if needed.,Common side effects include nausea, breast tenderness, and breakthrough bleeding, especially in the first few months.,Do not smoke while taking this medication, especially if over 35; smoking increases risk of serious cardiovascular events.,This pill does not protect against STIs; use condoms for protection.,Inform your healthcare provider of all medications and supplements you take, especially St. John's wort, antibiotics, and anticonvulsants.,Contact your doctor if you experience severe headache, chest pain, leg pain or swelling, sudden shortness of breath, or vision changes.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN 1/20 vs DESOGEN, answered by our medical review team.
LARIN 1/20 is a Combination Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity, inhibiting sperm penetration; alters endometrial receptivity.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN 1/20 and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN 1/20 is: One tablet (0.1 mg levonorgestrel/20 mcg ethinyl estradiol) orally once daily for 21 days followed by 7 placebo days.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN 1/20 and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN 1/20 is classified as Category C. LARIN 1/20 (norethindrone acetate/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects from low-dose OCs in cohort studies,. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.